Dupilumab (Dupixent)

Messages clés

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses dupilumab (Dupixent), 200 mg or 300 mg, single use syringe, solution for subcutaneous injection.
• Indication: As add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid–dependent asthma
• Reimbursement request: For patients with type 2 or eosinophilic asthma characterized by the following:
  • 2 or more clinically significant asthma exacerbations in the last 12 months and
    • blood eosinophils ≥ 150 cells/µL, or
    • fractional exhaled nitric oxide ≥ 25 parts per billion, or
    • treatment with maintenance oral corticosteroids, or
    • clinically allergen-driven asthma.